Severe mental disorders, depression and smoking cessation

2013 ◽  
Vol 14 (1) ◽  
pp. 77 ◽  
Author(s):  
L Yargic ◽  
Hayriye Baykan
Keyword(s):  
Smoking Cessation ◽  
Mental Disorders ◽  
Severe Mental Disorders

Is it Feasible and Effective to Help Patients with Severe Mental Disorders to Quit Smoking?

2017 ◽  
Vol 41 (S1) ◽  
pp. S32-S33
Author(s):  
J. Bobes
Keyword(s):  
Smoking Cessation ◽  
Mental Disorders ◽  
Real World ◽  
Suicide Attempts ◽  
Severe Mental Disorders ◽  
Open Label ◽  
Skin Reactions ◽  
Term Efficacy ◽  
Quit Smoking ◽  
Elevated Liver Enzymes

Despite the proven association between smoking and high rates of medical morbidity and reduced life expectancy in people with severe mental disorders (SMD), their smoking rates do not decline as they do in the general population. We carried out a non-randomized, open-label, prospective, 9-month follow-up multicentre trial to investigate the clinical efficacy, safety and tolerability of a smoking cessation programme designed for the treatment of patients with SMD in the community under real-world clinical conditions. A total of 82 patients were enrolled. Short-term efficacy: The 12-week 7-day smoking cessation (self-reported cigarettes per day =0 and breath CO levels ≤9 ppm) prevalence was 49.3%, with no statistically significant differences between medications (transdermal nicotine patches 50.0% vs. varenicline 48.6%, chi-square =0.015, P = 1.000). Long-term efficacy: At weeks, 24 and 36, 41.3 and 37.3% of patients were abstinent, with no statistically significant differences between treatments. Safety and tolerability: No patients made suicide attempts or required hospitalization. There was no worsening of the scores on the psychometric scales. In both groups, patients significantly increased weight, without significant changes in vital signs or laboratory results, with the exception of significant decreases in ALP y LDL-cholesterol levels in the varenicline group. Patients under varenicline more frequently presented nausea/vomiting (P < 0.0005), patients under TNP experienced skin reactions more frequently (P = 0.002). Three patients under varenicline had elevated liver enzymes. In conclusion, we have demonstrated that in real-world clinical settings it is feasible and safe to help patients with stabilized severe mental disorders to quit smoking.Disclosure of interestThis work was partly supported by the Spanish Ministry of Science and Innovation, Instituto de Salud Carlos III (FIS PI10/01758) and Fondos Europeos de Desarrollo Regional (FEDER). The Health Services of the Principado de Asturias, Spain, donated part of the medication used in this study.

Smoking cessation improves clinical outcome in severe mental disorders and is modulated by genetic variability at CHRNA5 gene

2020 ◽  
Vol 222 ◽  
pp. 516-519
Author(s):  
A.G. Segura ◽  
M. Mitjans ◽  
M. Fatjó-Vilas ◽  
M.P. Garcia-Portilla ◽  
L. Garcia-Alvarez ◽  
...  
Keyword(s):  
Smoking Cessation ◽  
Mental Disorders ◽  
Genetic Variability ◽  
Clinical Outcome ◽  
Severe Mental Disorders

P.6.d.014 Psychopathological tolerability of varenicline and nicotine patches for smoking cessation in severe mental disorders

2014 ◽  
Vol 24 ◽  
pp. S694
Author(s):  
L. González-Blanco ◽  
M.P. García-Portilla ◽  
L. García-Álvarez ◽  
P.A. Sáiz ◽  
C. Iglesias ◽  
...  
Keyword(s):  
Smoking Cessation ◽  
Mental Disorders ◽  
Severe Mental Disorders ◽  
Nicotine Patches

scholarly journals Effectiveness of a Multi-Component Smoking Cessation Support Programme (McSCSP) for Patients with Severe Mental Disorders: Study Design

2013 ◽  
Vol 11 (1) ◽  
pp. 373-389 ◽  
Author(s):  
Maria Garcia-Portilla ◽  
Leticia Garcia-Alvarez ◽  
Pilar Saiz ◽  
Eva Diaz-Mesa ◽  
Gonzalo Galvan ◽  
...  
Keyword(s):  
Smoking Cessation ◽  
Mental Disorders ◽  
Study Design ◽  
Severe Mental Disorders ◽  
Support Programme
Sign in / Sign up

Export Citation Format

Share Document